Spots Global Cancer Trial Database for Study of Nexavar (Sorafenib, BAY 43-9006) in Patients With Advanced Refractory Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Study of Nexavar (Sorafenib, BAY 43-9006) in Patients With Advanced Refractory Cancer
Official Title: Randomized Discontinuation Study of BAY 43-9006 in Patients With Advanced Refractory Cancer.
Study ID: NCT00079612
Conditions
Study Description
Brief Summary: The purpose of the study is to: * Find out if BAY 43-9006 prevents the growth of tumors * For patients who have stable cancer status after 3 months of treatment if it is safer and/or more effective to continue to give BAY 43-9006 or to stop giving BAY 43-9006 at that time. * Find out how long the effect of BAY 43-9006 is on tumors. To assess the safety of BAY 43-9006 (sorafenib) in the treatment of advanced refractory cancers. * Measure the amount of BAY 43-9006 and some of its targets in the blood stream in some patients.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
, Chicago, Illinois, United States
, Philadelphia, Pennsylvania, United States
, Houston, Texas, United States
, San Antonio, Texas, United States
, London, Greater London, United Kingdom
, Glasgow, Strathclyde, United Kingdom
, Sutton, Surrey, United Kingdom
Contact Details
Name: Bayer Study Director
Affiliation: Bayer
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
